SSO would like to thank the following companies for their support. Please select a name to learn more.
Zone Sponsors
AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.
The Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyze changes in the practice of medicine and transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.
Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients’ lives through science.
At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer. The potential to bring new hope to people with cancer drives our purpose and our commitment. As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.
Our purpose is to reimagine medicine to improve and extend people’s lives. We use innovative science and technology to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to reward those who invest their money, time and ideas in our company.
SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for patients with severe rare diseases and cancer. SpringWorks has a differentiated targeted oncology pipeline spanning solid tumors and hematological cancers, including two late-stage clinical trials in rare tumor types as well as several programs addressing highly prevalent, genetically defined cancers. For more information about SpringWorks Therapeutics, please visit www.springworkstx.com.
Engager Sponsors
Elucent Medical has designed the EnVisio™ Navigation system; a novel device that utilizes an innovative electromagnetic field and SmartClip™ to enable precise navigation within a wide field of view to a target of interest. The integration of the navigation tool onto the electrocautery device provides real-time guidance in the surgical field to deliver visual and audible indicators that provide Depth, Distance, and Direction to the SmartClip. This integrated system enables increased speed because of the ability to have the EnVisioTM pad providing localization of SmartClips, in addition to the Real-Time Navigation is within the surgeon’s hand. The guidance and localization update as the tissue is manipulated during the surgery. The generation of an unprecedentedly large field of the electromagnetic field for navigation, the EnVisio System, and SmartClip technology broaden the treatable patient population expanding SmartClip localization from the breast, and lymph nodes to the head and neck, abdominal soft tissue as well as the lung in the future. Elucent Medical is founded on the continued collaboration of multi-disciplinary physicians who seek to improve patient outcomes. The EnVisio Navigation system addresses the clinical need to meet the broadest patient demographics from simple (single site) to complex (several sites in the breast and axilla) cases allowing individualized treatment.
Lumicell is focused on improving surgical outcomes by utilizing its innovative fluorescence-guided surgical system to remove residual cancer that may have otherwise been left behind. The investigational Lumicell Direct Visualization System is designed to detect residual cancerous tissue within the breast cavity during the initial lumpectomy procedure. Lumicell’s proprietary optical imaging agent, LUMISIGHT, is also being explored across a wide variety of solid tumor indications. For more information, please visit www.illuminatecancerrealtime.com.
Signatera is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer. The Signatera test is personalized and tumor-informed, providing each individual with a customized blood test tailored to fit the unique signature of clonal mutations found in that individual’s tumor. Signatera is intended to detect and quantify cancer left in the body, at levels down to a single tumor molecule in a tube of blood, to identify recurrence earlier and to help optimize treatment decisions.
Perimeter Medical Imaging AI is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools that address unmet medical needs. Based in Toronto, with U.S. headquarters in Dallas, Texas, Perimeter aims to harness the power of big data, artificial intelligence, and machine learning technology to further its mission of improving the standard of care, providing better long-term outcomes for patients, and reducing healthcare costs.
Available now across the U.S., Perimeter’s S-Series OCT, powered by Optical Coherence Tomography, is designed to visualize tissues at the cellular level during surgical procedures, rather than days later when pathology reports come back. Our FDA-cleared technology gives surgeons cross-sectional visualization of surgical margins and excised tissues in real time, with 10x higher image resolution than standard X-ray and ultrasound, and 100x greater than MRI.
Our next-generation technology will use ImgAssist AI, a powerful artificial intelligence and machine learning tool designed to assist surgeons with visualizing margins. In November 2021, Perimeter received FDA Investigational Device Exemption (IDE) approval and launched a multi-site, randomized clinical trial using Perimeter B-Series OCT with ImgAssist AI. The study evaluates this system against the current standard of care and assesses the impact on re-operation rates for patients undergoing breast conservation surgery. For more information, visit www.perimetermed.com
Replimune’s tumor-directed oncolytic immunotherapies have the potential to redefine the cancer treatment paradigm. Replimune’s approach brings together multiple mechanisms of action to destroy the tumor, ignite an anti-cancer response, and generate long-lived immune activity. The ultimate aim is to improve outcomes for patients with cancer.
Replimune’s tumor directed oncolytic immunotherapies belong to a novel class of cancer therapeutics and are designed with a dual mechanism of action. Replimune treatments work by directly destroying tumors and altering the tumor microenvironment (TME), thereby releasing tumor derived antigens in an immuno-stimulatory fashion. This induces a powerful and durable systemic immune response against a patient’s own cancer.
While oncolytic immunotherapies have shown clinical activity against tumors when given as single agents, we expect these therapies to combine with and enhance the effectiveness of several different modalities and treatments — including immunotherapy, chemotherapy, small molecules and radiation — because of the synergistic MOA and well-established safety profile.
Sirtex Medical is a global healthcare business with offices in the U.S., Australia, Germany and Singapore, working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres.
Supporter Sponsors
AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, vascular interventions & therapies, & oncology. Diverse product lines include market-leading ablation systems, vascular access products, angiographic products & accessories drainage products, thrombolytic products & venous products. Learn more at angiodynamics.com.
Castle Biosciences is a skin cancer diagnostics company focused on providing physicians and patients with personalized, clinically actionable genomic information enabling more accurate treatment plan decisions. From its formation in 2008, Castle Biosciences has applied emerging artificial intelligence techniques in molecular diagnostics to improve patient care and outcomes. Our DecisionDx family of molecular diagnostic tests have the ability to meaningfully impact how cancers are diagnosed and managed (castletestinfo.com).
Clarix Imaging brings unprecedented clarity to intraoperative breast cancer lumpectomy margin visualization with our true 3D (CT) VSI-360™ Volumetric Specimen Imaging System. This advanced imaging technology takes breast surgeons and radiologists on a Journey Through the Specimen™ with views of any tissue slice from multiple angles – with no obscuring of the margins. Clarix Imaging is the only company to commercially offer a CT breast specimen imaging system. A venture-backed private company founded by world-renowned medical imaging scientists from the University of Chicago, Clarix Imaging’s mission is to empower clinicians with clear tumor visualization and intelligent analysis for precision and personalized medicine based on breakthrough innovations in imaging science and AI. Our first product is the FDA cleared true 3D VSI-360™, which offers radiologists and surgeons unprecedented clarity for intraoperative specimen margin visualization in breast cancer surgeries such as lumpectomy – right inside the operating room. VSI-360™ generates a true 3D image of the specimen in real-time, and its advanced software tools allow users to visualize the tumor in thin image slices without overlapping tissues obscuring the margins. Partner with us on our journey to advance outcomes in surgical oncology through innovations in imaging.
Hologic is a global medical technology company specializing in women’s health and well-being. We offer innovative solutions for screening, detecting, and treating conditions and diseases that affect women throughout their lives, including breast, gynecological and skeletal issues; cervical cancer testing; and sexually transmitted diseases. As a science-driven company, our products are backed by clinical evidence, ensuring that they perform as intended, so healthcare professionals can have greater certainty in their decisions and patients, greater peace of mind.
Iovance Biotherapeutics
aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to fighting cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. Our lead late-stage TIL product candidate, lifileucel for metastatic melanoma, has the potential to become the first approved one-time cell therapy for a solid tumor cancer. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit www.iovance.com.
At KUBTEC®, our passion is developing transformative specimen imaging, breast cancer margin management, and specimen radiography systems that enable medical professionals to provide the best quality of care for their patients. Our proprietary award-winning technologies, such as 3D breast specimen tomosynthesis; advanced, high-resolution specimen X-ray imaging; and intelligent workflow management features, are redefining specimen radiography and breast cancer surgery standards for the 21st century. The KUBTEC MOZART® System provides breast surgeons and radiologists with the clearest view of their surgical margins, right there in the Operating Room, and is clinically demonstrated to facilitate reductions in re-excision rates by up to 50%. The Mozart System uses 3D tomosynthesis for breast specimen imaging, transforming KUBTEC specimen radiography into the most advanced, accurate tool for the intraoperative management of surgical margins.
Merit Oncology is on a mission to reduce the burden cancer places on patients and their loved ones. As a provider of world class solutions for the diagnosis, localization, and treatment of cancer, Merit Oncology consistently invests in improving our technologies and innovating new platforms to meet our physicians’ needs. The preferred localization solution to treat more patients, the SCOUT® Radar Localization system has been clinically proven in over 385,000 breast and soft tissue localizations and is referenced in over 75 clinical publications. The technology represents unparalleled accuracy, can be placed under all imaging modalities, and will not interfere with imaging interpretation, including MRI. It is uniquely suited to be placed at any time prior to surgery, including prior to neoadjuvant chemotherapy. The SCOUT system has been clinically demonstrated to improve patient outcomes, workflow and significantly reduce OR delays. Easing the burden of breast cancer treatment, SAVI® Brachy offers a strut-based approach to tissue-sparing dosimetry and is designed to maximize ease of use during placement while providing unparalleled dose customization. Three-fraction treatment protocol with SAVI allows effective APBI treatment to be completed in as little as 2 days, sparing healthy tissue and significantly reducing patient treatment time
MOLLI Surgical started in the operating room, where surgeons were using dated tools to treat cancer patients — and we knew we could do better. Our surgical wand is precise, reliable, easy to use, and built with the realities of the operating room in mind. More importantly, it is built with patients in mind. Our technology replaces procedures to mark lesions with one that is more precise, efficient, and cost-effective. MOLLI Surgical is proud to build the advanced equipment that patients prefer to have and that physicians prefer to use.
obp is the leading global developer of single-use, self-contained, illuminating surgical devices. We integrate light with device — making them one — creating effective and simplified single-use solutions. Our innovative products are used in surgery centers and hospitals throughout the U.S., as well as healthcare facilities worldwide.
Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. The company is also developing innovative interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain, and spasticity. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesia currently approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.